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Lipid redistribution  
in renal dysfunction
Xiong Z. Ruan1, John F. Moorhead1 and Zac Varghese1
Zhao et al. demonstrated that chronic renal failure was associated with 
lipid redistribution in the kidney and other organs. We discuss three 
types of lipid redistribution in the context of inflammatory stress, which 
might help to explain many conflicting clinical observations in relation 
to lipid-mediated renal and vascular injury. An assessment of lipid 
redistribution may provide a new target for therapeutic intervention.
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In 1982 Moorhead and colleagues sug-
gested that the compensatory hepatic 
synthesis of lipoproteins in response 
to urinary loss of albumin could cause 
progressive renal disease and that patho-
genesis of atherosclerosis and glomerulo-
sclerosis could have a common pathway. 
This hypothesis focused on the possibility 
that lipoprotein-induced nephron damage 
could result in progressive renal disease. 
Since then, many studies using different 
animal models of either diet-induced 
hyperlipidemia or renal dysfunction 
induced by subtotal nephrectomy have 
supported the hypothesis that lipid abnor-
malities contributed to the progression of 
renal injury, and lipid-lowering strategies 
showed beneficial effects. As most of these 
studies involved five-sixths nephrectomy, 
the renal failure was relatively acute and 
severe, and observation periods were usu-
ally shorter than 4 months. Zhao et al.1 
(this issue), using a unilaterally nephrec-
tomized Sprague-Dawley rat model over 
a 10-month observation period, demon-
strated that the resulting renal impairment 
caused renal adipose tissue accumulation. 
The recent Treating to New Targets (TNT) 
study, in which a total of 10,001 patients 
with coronary heart disease were ran-
domly assigned to double-blind therapy 
with 10 or 80 mg per day atorvastatin, 
showed that glomerular filtration rate 
improved in both groups, with greater 
improvement in patients who received 
the higher dose, clearly demonstrating 
that atorvastatin was nephroprotective 
in people with coronary heart disease. 
Together these data provide further sup-
port for lipid-mediated progression of 
renal disease.
In their uninephrectomized (UNX) 
Sprague-Dawley rat model, Zhao et al.1 
provide morphological evidence that 
UNX rats had adipose redistribution to 
the kidney from the peri-renal capsule, 
omentum, mesenteries, and abdominal 
wall. At 4, 7, and 10 months postopera-
tion, fat deposits in the peri-renal capsule, 
omentum, mesenteries, and abdominal 
walls were significantly diminished in 
the UNX rats in comparison with sham 
controls, and increased ectopic fat depos-
its were found in the remnant kidneys 
(mainly in the inner cortex) and other 
solid organs (liver, pancreatic islets, 
and adrenal glands). It was particularly 
interesting to note that the angiotensin-
converting enzyme inhibitor lisinopril 
protected renal tissue from injury and 
lipid deposition, an important finding, 
although a cause-and-effect association 
was not fully established in this study.
Until recently, adipose tissue has been 
thought to be a mere storage depot for 
triglycerides and cholesterol esters as 
lipid droplets, but it is now clear that 
adipocytes are metabolically active endo-
crine cells that play a central role in over-
all energy homeostasis, are an important 
source of inflammatory cytokines, and 
affect some aspects of the innate and 
adaptive immune systems.2 Adipose tis-
sue contains many different cell types, 
including adipocytes, stem cells, mono-
cytes, macrophages, endothelial cells, 
vascular smooth muscle cells, fibrob-
lasts, and extracellular matrix, charac-
teristics that allow it to be considered 
a mini-organ with a capillary network. 
Adipocyte- derived peptides, cytokines, 
and complement factors act in an auto-
crine and paracrine way to regulate 
adipocyte metabolism and growth, as 
well as being endocrine and inflamma-
tory signals.
The apparent movement or redistri-
bution of adipose tissue reported in this 
study could have other implications for 
both the pathogenesis of renal disease 
and its progression. The well-known 
association of partial lipodystrophy and 
mesangiocapillary glomerulonephritis 
could in theory support the finding of 
adipose tissue translocation to kidney 
and other organ systems.
Zhao and colleagues1 showed ectopic 
lipid redistribution using only hema-
toxylin and eosin and periodic acid-
Schiff stains, but detailed longitudinal 
studies using computed tomography or 
magnetic resonance imaging scanning 
would be required to follow adipose tis-
sue redistribution. Nor is it clear whether 
the authors posit extracellular neutral fat 
redistribution or intracellular accumula-
tion of lipids through foam-cell forma-
tion. Further in-depth analysis is needed 
to evaluate the cellular component of the 
translocated adipose tissue and its inter-
action with intrinsic and extrinsic renal 
cells and their transformation. Though fat 
accumulated in the kidney may indeed 
be translocated from other fatty tissue, it 
is also possible that intrinsic renal cells 
such as the mesangial cell could be dif-
ferentiated to adipocytes or foam cells. In 
this context, specific cell markers should 
be investigated. The available evidence 
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suggests that adipose tissue links many 
facets of the metabolic syndrome, includ-
ing dyslipidemia, insulin resistance, 
and hypertension.
The role of chronic inflammation, 
which causes both peripheral fat loss and 
central fat gain in human immunodefi-
ciency virus infection and is present in 
chronic renal failure patients, may also 
contribute to tissue fat redistribution as 
demonstrated in the paper by Zhao et al.1 
Translocated adipose tissue itself could 
be the source of the inflammatory stress. 
It is becoming increasingly clear that 
inflammation is a major contributory fac-
tor in the pathogenesis of athero sclerosis 
and, when persistent, may have a major 
role in aggravating lipid-mediated renal 
and vascular injury.
Anthropometric data such as the waist–
hip ratio have been used to investigate 
both regional adipose tissue distribution 
and metabolic profile in the assessment 
of risk factors for diabetes and cardiovas-
cular disease. Lipid levels are also widely 
used to predict the risk of lipid-mediated 
vascular and renal injury and to evaluate 
the clinical effect of lipid-lowering drugs. 
This may not be a problem in the general 
population, where lipid homeostasis and 
distribution are normal. However, normal 
physiological distribution and homeo-
stasis could be disrupted by chronic renal 
dysfunction. For example, in hemodialysis 
patients there is an apparently contradic-
tory association between cardiovascular 
risk, which is increased up to 33-fold, and 
low plasma cholesterol. We have raised the 
possibility, supported by extensive in vitro 
evidence from our laboratory, that chronic 
inflammation may be at the root of this 
paradox. Inflammation fundamentally 
modifies cellular cholesterol homeostasis 
so as to redistribute lipid from the circu-
lation to the peripheral tissues (kidney 
and vessels) (Figure 1). Our data suggest 
that inflammation increases intracellular 
cholesterol influx into renal and arterial 
tissue (vascular smooth muscle cells, 
macrophages, and mesangial cells) by 
inducing scavenger receptor expression, 
disrupting low-density lipoprotein (LDL) 
receptor feedback regulation, and caus-
ing unrestrained LDL receptor- mediated 
uptake.3 Inflammation also decreases 
cholesterol efflux from peripheral tissue,4 
implying that it modifies cholesterol traf-
ficking, which could result in cholesterol 
redistribution from the circulation to 
the peripheral tissues (renal and vascu-
lar) and a lower circulating cholesterol 
level in patients with chronic inflamma-
tory diseases. This is also supported by a 
recent prospective clinical study show-
ing that inflammatory stress character-
ized by increased C-reactive protein or 
interleukin-6 is one of the factors driv-
ing the reverse cholesterol epidemiol-
ogy described above.5 Thus, the use of 
circulating cholesterol levels as a predic-
tive marker for cardiovascular risk or to 
evaluate a drug effect on lipid lowering 
in patients with chronic inflammation, 
including those with chronic renal dys-
function or type 2 diabetes, is unreliable 
and may even be misleading.
There may be yet another type of 
intracellular lipid redistribution: from 
organelle to organelle. We and oth-
ers have previously demonstrated 
that inflammatory stress causes lipid 
accumulation in the endoplasmic 
reticulum, which causes endoplasmic 
reticulum stress. In addition to total con-
tent, lipid relocation at this level could be 
critical, potentially triggering lipid- 
induced apoptosis.
Other interesting points in the paper 
by Zhao et al.1 include a demonstration 
that peri-renal adipose tissues contained 
mainly large unilocular cells in sham 
experimental rats, polygonal multilocu-
lar cells in UNX rats, and mixed unilocu-
lar and multilocular cells in treated UNX 
rats. A shift in fat topography could aid 
investigation of the pathogenesis of 
lipid-mediated vascular and renal and 
other organ injury. Adipocyte size may 
be important in relation to metabolic 
potential, so that downsizing of large 
unilocular adipocytes into multilocular 
cells could cause diminished peri-renal 
adipose mass induced by uninephrec-
tomy. It would be interesting to know 
whether this transformation is present 
in local or systemic insulin resistance.
Angiotensin II is produced locally in 
adipose tissue and can induce transfor-
mation of preadipocytes into mature adi-
pocytes. The authors demonstrated that 
angiotensin-converting enzyme inhibi-
tor treatment seems to prevent adipose 
redistribution, adipocyte transformation, 
and lipid peroxidation, potentially add-
ing to the value of lipid-lowering com-
pounds. It has recently been reported 
that inducible ablation of adipocytes 
blunts lipopolysaccharide-stimulated 
figure 1 | Diagram of three types of lipid redistribution and their consequences in renal 
dysfunction. ER, endoplasmic reticulum.
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systemic levels of interleukin-6 in mice. 
It has also been shown that treatment of 
diabetes with thiazolidinediones selec-
tively increases fat partitioning to the 
subcutaneous adipose depot but does 
not change visceral fat accumulation.6 It 
is possible that thiazolidinediones could 
prevent all three types of fat redistribu-
tion discussed in this Commentary.
In summary, tissue lipid redistribution 
and accumulation in response to 
inflammation may occur at several lev-
els and sites: from circulation to tissue, 
tissue to tissue, and organelle to organelle 
(Figure 1). Human adipose tissue does 
not exist in isolation in different anatomic 
locations, and a best-fit relationship in 
terms of volume and function among 
different fat depots needs to be met to 
maintain energy homeostasis and prevent 
obesity-related complications. Therefore, 
the topography of adipose tissue is an 
important and timely addition to con-
ventional measurements of plasma lipid 
concentration and increases understand-
ing of the pathogenesis of lipid-mediated 
renal and vascular injury while providing 
new targets for therapeutic intervention.
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Does an apple a day put 
hypertension in play?
Joachim Jankowski1 and Thomas Günthner1
Singh et al. offer exciting data in their new report about fructose-induced 
hypertension. Fructose induced an increase in serum uric acid after 8–10 
weeks of increased fructose exposure, but no correlation was found 
between hyperuricemia and hypertension.
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Research on the role of fructose has 
increased but has demonstrated ambigu-
ous outcomes. Although some showed 
that fructose markedly lowers postpran-
dial hyperglycemia and hyperinsulinemia1 
and improves glucose tolerance in type 2 
diabetes patients,2 the majority of publica-
tions found no benefits. Fructose has been 
described as an elicitor of insulin resistance, 
dyslipidemia, disordered carbohydrate 
metabolism, hypertension, and obesity.3,4 
Singh et al.5 (this issue) now describe a 
fructose-induced increase in serum uric 
acid after 8–10 weeks of increased fruc-
tose exposure, which was also found by 
Nakagawa et al.6 However, unlike those 
authors, Singh et al.5 found no correlation 
between hyperuricemia and hypertension. 
This association needs to be taken into con-
sideration by Singh et al., who consider it 
a consequence of salt overload and hyper-
volemia. A recently published study reveals 
that the fructose transporter SLC2A9 also 
transports uric acid and hence may provide 
the explanation for hyperuricemia.7
Singh et al.5 impressively demonstrate 
an increased expression of the apical 
chloride-absorbing transporter (PAT1/
Slc26a6) and the fructose-absorbing 
transporter (Glut5/Slc2a5) in the small 
intestine in mice, stimulated by increased 
dietary fructose intake. The outstanding 
findings of their paper clarify the mecha-
nism of fructose-induced hypertension. 
The study is well designed, and the data 
presented are valid. However, the number 
of animals used in the experiments is very 
limited: three, four, and five. A uniform 
number of animals would be desirable. 
Another weakness of the study is the sole 
use of a 40 mM concentration of fruc-
tose solution, which is rather high. An 
analysis and comparison of the observed 
effects using additional lower concentra-
tions would probably deliver information 
regarding a dose–response relationship.
The authors proved an interaction 
between the two above-mentioned trans-
porters.5 The fructose-induced increase 
in intestinal chloride absorption and a 
simultaneous decrease in renal chloride 
excretion led to salt overload and eventu-
ally generated hypertension in Slc26a6+/+ 
mice. Fructose-induced blood pressure 
elevation was 9 ± 1.3 mm Hg in Slc26a6+/+ 
and 3 ± 0.3 mm Hg in Slc26a6–/– mice. 
On the other hand, the plasma fructose 
increase was comparable in Slc26a6+/+ and 
Slc26a6–/– mice, which indicates that dele-
tion of Slc26a6 did not affect the absorption 
of fructose in the intestine. These effects 
were confirmed in experiments in Sprague-
Dawley rats. Increased dietary fructose 
significantly elevated systolic blood pres-
sure as compared with a control diet. The 
removal of chloride from the high-fructose 
diet blocked fructose-induced hyperten-
sion by 70% when compared with the 
chloride-free diet alone and by 100% when 
compared with the control diet.
